CSIMarket Company Name, Ticker, Customers, else..
 
60 Degrees Pharmaceuticals Inc   (NASDAQ: SXTP)
 

60 Degrees Pharmaceuticals Inc's Suppliers Performance

SXTP's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
SXTP Costs vs Sales of Suppliers Growth 60 Degrees Pharmaceuticals Inc recorded an increase in cost of sales by 201.6 % year on year, sequentially cost of sales grew by 76.28 % in Q2.

• More on SXTP Suppliers



60 Degrees Pharmaceuticals Inc recorded increase in cost of sales by 201.6 % year on year, sequentially cost of sales grew by 76.28 % in Q2.

• More on SXTP Suppliers




60 Degrees Pharmaceuticals Inc's Comment on Supply Chain


The company sources raw materials (API) with support from a USAMMDA grant. Current inventory is short-dated and requires replacement by early Q2 2026. Inventory write-offs increased temporarily due to scaling operations but are not expected to recur. Larger-scale production processes are planned to reduce inventory costs. Research revenues increased significantly due to a new USAMMDA contract for commercial validation of packaging for Arakoda and a contract with the University of Kentucky for tafenoquine clinical trial supply. Research and development costs decreased primarily due to non-cash charges in 2024 related to share-based payments to vendors. Kentucky Technology, Inc. delivered a report on SJ733 and tafenoquine development, while Trevally completed synthesis of castanospermine. Research and development expenses also included costs related to a babesiosis trial for tafenoquine and commercial validation and packaging of Arakoda.

60 Degrees Pharmaceuticals Inc's Comment on Supply Chain


The company sources raw materials (API) with support from a USAMMDA grant. Current inventory is short-dated and requires replacement by early Q2 2026. Inventory write-offs increased temporarily due to scaling operations but are not expected to recur. Larger-scale production processes are planned to reduce inventory costs. Research revenues increased significantly due to a new USAMMDA contract for commercial validation of packaging for Arakoda and a contract with the University of Kentucky for tafenoquine clinical trial supply. Research and development costs decreased primarily due to non-cash charges in 2024 related to share-based payments to vendors. Kentucky Technology, Inc. delivered a report on SJ733 and tafenoquine development, while Trevally completed synthesis of castanospermine. Research and development expenses also included costs related to a babesiosis trial for tafenoquine and commercial validation and packaging of Arakoda.







SXTP's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
60 Degrees Pharmaceuticals Inc 2.76 1.11 -8.11 3
SUBTOTAL 0.00 0.00 0.00 -


Sources: 60 Degrees Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on 60 Degrees Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.